Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + Neoadjuvant Chemo in Osteosarcoma
NCT04294511Phase 2Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Dec 2019
- Primary completion
- Mar 2021
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab in osteosarcoma (OS), sponsored by Sun Yat-sen University. Status: unknown.
02
Drugs
camrelizumab
03
Conditions
osteosarcoma (OS)
Beyond the preview
Go deeper on NCT04294511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04294511.